Jing Lin
Visit Investigator ProfileInvestigation Details
Parmesh Dutt , Nicholas Geagan , Varsha Garnepudi , Erin Hill , Nabil Al-Humadi , Emnet Yitbarek , Xiuju Lu , Yun Lu , Luisa Virata , Osman Yogurtcu , Ross Peterson , Firoozeh Alvandi , Ho-Hsiang Wu , Roberta Lynne Crim , Hsiaoling (Charlene) Wang , Marina Zaitseva , Tao Pan , Oluchi Elekwachi , Ching Yim-Banzuelo , Ewan Plant , Jie He , Judy Beeler , Simleen Kaur , Hyesuk Kong , Santosh Nanda , Ritu Agarwal , Brenda Baldwin , Malcolm Nasirah , George Kastanis , Daphne Stewart
Detailed Analysis
Investigator Jing Lin takes a meticulous approach to inspecting GMP compliance and quality systems, prioritizing the identification of deficiencies and non-compliance in manufacturing practices and testing procedures.
Investigator Jing Lin is particularly focused on GMP compliance and quality systems in both drug substance and drug product manufacturing. He pays close attention to production and process controls, manufacturing practices, and quality control testing, and emphasizes adherence to standard protocols and regulations. He is concerned about potential risks in product safety and efficacy.
Unlock Insights from 483s & Stay Audit Ready with FDA Tracker
Monitor FDA Six Systems, Analyse 483s with Observations, Investigators & Companies